Robert G. Moussa(5)(6)
Robert G. Moussa has served as a director of Derma Sciences since May 2005.
Mr. Moussa is the Chairman, President and Chief Executive Officer of Dilon Technologies, Inc., makers of a gamma imaging system for early breast cancer detection, a position he has held since February 2008.
Before joining Dilon Technologies, Inc., Mr. Moussa served as President and Chief Executive Officer of Robert Moussa & Associates, a consulting firm serving the pharmaceutical, biotechnology and healthcare industries.
Prior to founding this firm, he served in a variety of executive positions with Mallinckrodt, Inc., St. Louis, Missouri, a $2.4 billion healthcare and chemical company.
Mr. Moussa’s most recent assignment at Mallinckrodt, Inc. was President — International, a position he held from 1995 through 1997.
Previously, he served from 1992 to 1996 as President and Chief Executive Officer of Mallinckrodt Medical, Inc., Mallinckrodt, Inc.’s largest business unit with over $1 billion dollars in revenues.
Before joining Mallinckrodt Medical, Inc., Mr. Moussa served during the period 1978 through 1992 as Mallinckrodt, Inc.’s Group Vice President — International Medical Products, Vice President and General Manager — Medical Products Europe, General Manager — Critical Care, Director of Business Operations and General Sales Manager.
Prior to joining Mallinckrodt, Inc., Mr. Moussa held a number of positions during the period from 1969 through 1976 with Sherwood Medical, United Kingdom, most recently as Director of Marketing.
Baccalaureate from the Collége du Sacre-Cœur, Beirut, Lebanon, in 1966 and his
Bachelor of Science in Business Administration from Ealing University
, London, England, in 1969.
has also completed executive seminars at the University of California at Berkeley, the Aspen Institute, the Wharton Executive School and the Center for Creative Leadership
We believe that Mr. Moussa’s qualifications to serve on our Board of Directors include his many years of experience as senior and chief executive with leading companies in the pharmaceutical and healthcare industries.
Robert G. Moussa(6)
was granted 6,500 restricted share units in 2013 that will vest in 2014.
At December 31, 2013, Mr. Moussa
had 43,500 vested outstanding option awards and 17,750 unvested restricted share unit awards.
Edward J. Quilty, Stephen T. Wills, CPA, MST, C. Richard Stafford, Esq., Robert G. Moussa, Bruce F. Wesson, Brett Hewlett, Srini Conjeevaram and Paul M. Gilbert attended last year’s annual stockholders’ meeting.
We maintain a Compensation Committee that is currently composed of Robert G. Moussa, Chairman, Stephen T. Wills, CPA, MST and Amy Paul.
and Wills and Ms. Paul are considered to be “independent” as defined in NASDAQ Marketplace Rule 5605(a)(2).
We maintain a Nominating and Corporate Governance Committee that is currently composed of Bruce F. Wesson, Chairman, C. Richard Stafford, Esq., Robert G. Moussa and Srini Conjeevaram.
Wesson, Stafford, Moussa
and Conjeevaram are considered to be “independent” as defined in NASDAQ Marketplace Rule 5605(a)(2).